ESR1 and breast cancer: We also asked whether enzalutamide affects CRAT protein expression in primary ER+ BC samples from a neoadjuvant clinical trial our group conducted examining efficacy of the ER degrader fulvestrant alone vs in combination with enzalutamide (52).